1-3 of 3
Nisha Philipose
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Clinical Trials & Observations
Eunice S. Wang, Pau Montesinos, Mark D. Minden, Je-Hwan Lee, Michael Heuser, Tomoki Naoe, Wen-Chien Chou, Kamel Laribi, Jordi Esteve, Jessica K. Altman, Violaine Havelange, Anne-Marie Watson, Carlo Gambacorti-Passerini, Elzbieta Patkowska, Shufang Liu, Ruishan Wu, Nisha Philipose, Jason E. Hill, Stanley C. Gill, Elizabeth Shima Rich, Ramon V. Tiu
Journal: Blood
Blood (2022) 140 (17): 1845–1857.
https://doi.org/10.1182/blood.2021014586
Published: 2022
Includes: Supplemental data
Journal Articles

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Eunice S. Wang, Pau Montesinos, Mark D. Minden, Je-Hwan Lee, Michael Heuser, Tomoki Naoe, Wen-Chien Chou, Kamel Laribi, Jordi Esteve, Jessica K. Altman, Violaine Havelange, Anne-Marie Watson, Elzbieta Patkowska, Shufang Liu, Ruishan Wu, Nisha Philipose, Jason E. Hill, Stanley Gill, Elizabeth Shima Rich, Ramon V. Tiu
Journal: Blood
Blood (2021) 138 (Supplement 1): 700.
https://doi.org/10.1182/blood-2021-145379
Published: 2021
Journal Articles

A Phase 1, Dose-Escalation Study of Gilteritinib Combined with Chemotherapy in Patients Aged 6 Months to <21 Years with FLT3 Internal Tandem Duplication-Positive Relapsed or Refractory AML

Philip Connor, Linyi Fan, Stanley Gill, Jason E. Hill, Nisha Philipose, David Delgado, Ramon V. Tiu, Dirk Reinhardt
Journal: Blood
Blood (2021) 138 (Supplement 1): 2315.
https://doi.org/10.1182/blood-2021-147862
Published: 2021